Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Xetra  >  MorphoSys AG    MOR   DE0006632003

End-of-day quote. End-of-day quote  - 05/05
42.815 EUR   -1.40%
05/04 MORPHOSYS : to Present at Three Upcoming Conferences
05/03 MORPHOSYS : AG Reports Results for the First Three Months of 2016
04/27 MORPHOSYS : to Host Q1 2016 Conference Call on May 3, 2016
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Xetra
04/29/2016 05/02/2016 05/03/2016 05/04/2016 05/05/2016 Date
43.7(c) 43.73(c) 43.165(c) 43.425(c) 42.815 Last
98 053 74 380 93 837 77 065 27 275 Volume
-3.82% +0.07% -1.29% +0.60% -1.40% Change
More quotes
Financials (€)
Sales 2016 49,0 M
EBIT 2016 -66,5 M
Net income 2016 -47,1 M
Finance 2016 118 M
Yield 2016 -
Sales 2017 67,9 M
EBIT 2017 -38,4 M
Net income 2017 -27,4 M
Finance 2017 88,4 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 21,1x
EV / Sales 2017 15,7x
Capitalization 1 153 M
More Financials
Company
MorphoSys AG engages in the development of antibodies for therapeutic, diagnostics, and research applications.It operates through the following segments: Partnered Discovery, Proprietary Development and AbD Serotec.The Partnered Discovery segment involves technologies for the generation of human... 
Sector
Biotechnology & Medical Research
Calendar
05/05 | 03:20pmPresentation
More about the company
Surperformance© ratings of MorphoSys AG
Trading Rating : Investor Rating :
More Ratings
Latest news on MORPHOSYS AG
05/04 MORPHOSYS : to Present at Three Upcoming Conferences
05/03 MORPHOSYS : AG Reports Results for the First Three Months of 2016
04/27 MORPHOSYS : to Host Q1 2016 Conference Call on May 3, 2016
04/21 MORPHOSYS AG : MorphoSys Provides Update on Results From Partner's Phase 2b/3 RE..
04/21 AD HOC : MorphoSys Provides Update on Results From Partner's Phase 2b/3 RESILIEN..
04/20 MORPHOSYS : Licensing Partner GSK Starts Phase 2 Study with GSK3196165 (MOR103) ..
04/20 MORPHOSYS AG : Announcement of the Convening of the AGM in Munich/Germany on Jun..
04/18 MORPHOSYS : Licensing Partner GSK Starts Phase 2 Study with GSK3196165 (MOR103) ..
More news
Sector news : Biotechnology & Medical Research - NEC
08:27pDJSANOFI : Will Try to Oust Medivation Board Unless Deal Talks Start -- Update
07:38pDJREGENERON PHARMACEUTICALS : Raises Sales Expectations for Eylea -- Update
06:57p MEDIVATION : Reiterates Rejection of Sanofi's Substantially Inadequate Proposal
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
05/03 MorphoSys' (MPSYF) CEO Simon Moroney on Q1 2016 Results - Earnings Call Trans..
05/03 MorphoSys AG reports Q1 results
03/11 Upcoming Events - Pivotal Data For Novartis And Perhaps Aduro Too
03/02 MorphoSys' (MPSYF) CEO Simon Moroney on Q4 2015 Results - Earnings Call Trans..
03/02 MorphoSys AG reports Q4 results


Comments 
Advertisement
Chart MORPHOSYS AG
Duration : Period :
MorphoSys AG Technical Analysis Chart | MOR | DE0006632003 | 4-Traders
Full-screen chart
Technical analysis trends MORPHOSYS AG
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions